Why the study?
The prognostic importance of increased visit-to-visit blood pressure variability for future microvascular and macrovascular complications in type 2 diabetes has been scarcely investigated and remains unsettled.
Does visit-to-visit blood pressure variability predict micro- and macrovascular outcomes in patients with type 2 diabetes?
Does visit-to-visit blood pressure variability predict micro- and macrovascular outcomes in patients with type 2 diabetes?
Systolic visit-to-visit blood pressure variability independently predicts MACE in type 2 diabetes but does not improve cardiovascular risk stratification beyond mean blood pressure levels.
Answers are grounded in this paper and cite their sources.
BP variability adds negligible discrimination beyond mean BP in T2D; hypothesis-generating and should not yet alter risk stratification.
BACKGROUND: The prognostic importance of an increased visit-to-visit blood pressure variability (BP-VVV) for the future development of micro- and macrovascular complications in type 2 diabetes has been scarcely investigated and is largely unsettled. We aimed to evaluate it in a prospective long-term follow-up study with 632 individuals with type 2 diabetes. METHODS: BP-VVV parameters (systolic and diastolic standard deviations [SD] and variation coefficients) were measured during the first 24-months. Multivariate Cox analysis, adjusted for risk factors and mean BP levels, examined the associations between BP-VVV and the occurrence of microvascular (retinopathy, microalbuminuria, renal function deterioration, peripheral neuropathy) and macrovascular complications (total cardiovascular events [CVEs], major adverse CVEs [MACE] and cardiovascular and all-cause mortality). Improvement in risk discrimination was assessed by the C-statistic and integrated discrimination improvement (IDI) index. RESULTS: Over a median follow-up of 11.3 years, 162 patients had a CVE (132 MACE), and 212 patients died (95 from cardiovascular diseases); 153 newly-developed or worsened diabetic retinopathy, 193 achieved the renal composite outcome (121 newly-developed microalbuminuria and 95 deteriorated renal function), and 171 newly-developed or worsened peripheral neuropathy. Systolic BP-VVV was an independent predictor of MACE (hazard ratio: 1.25, 95% CI 1.03-1.51 for a 1-SD increase in 24-month SD), but not of total CVEs, cardiovascular and all-cause mortality, and of any microvascular outcome. However, no BP-VVV parameter significantly improved cardiovascular risk discrimination (increase in C-statistic 0.001, relative IDI 0.9%). CONCLUSIONS: Systolic BP-VVV was an independent predictor of MACE, but it did not improve cardiovascular risk stratification. The goal of anti-hypertensive treatment in patients with type 2 diabetes shall remain in controlling mean BP levels, not on decreasing their visit-to-visit variability.
No takes yet. Share an insight, caveat, or question.
Cardoso et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: